MedeliX
Start asking

rimegepant

Vydura · ATC code N02CD06

Key facts
Active substance
rimegepant
Drug class
Antimigraine
ATC code
N02CD06
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
VYDURA 75 mg oral lyophilisate
Marketing authorisation holder
Pfizer Europe MA EEIG
Information as of
2026-10-27

Key facts

Rimegepant is a CGRP receptor antagonist (gepant; Vydura oral lyophilisate). It is used in adults for acute treatment of migraine and for prevention of episodic migraine.

What it is used for

  • Acute treatment of migraine with or without aura in adults
  • Preventive treatment of episodic migraine in adults with at least 4 migraine attacks per month

Dosing

  • Acute treatment: 75 mg as needed, once daily
  • Prophylaxis: 75 mg every other day or every day, individualised by efficacy and tolerability
  • Maximum 75 mg per day; place the lyophilisate on or under the tongue, no liquid needed
  • With moderate CYP3A4 inhibitors or strong P-gp inhibitors, avoid another dose within 48 hours
  • No adjustment in renal impairment or mild to moderate hepatic impairment; avoid in end-stage renal disease and severe hepatic impairment

Contraindications

  • Hypersensitivity to the active substance or any excipient

Important warnings

  • Hypersensitivity reactions including dyspnoea and severe rash, which can occur days after administration
  • Strong CYP3A4 inhibitors and strong or moderate CYP3A4 inducers are not recommended
  • Caution with frequent use in severe renal impairment

Side effects

  • Acute treatment: most common nausea (1.2%), mostly mild or moderate
  • Prophylaxis: most common nausea and constipation
  • Uncommon: hypersensitivity including dyspnoea and severe rash; anaphylactic reactions reported

Interactions

  • Strong CYP3A4 inhibitors (e.g. clarithromycin, itraconazole, ritonavir): not recommended; itraconazole increased AUC 4-fold
  • Moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole) may increase exposure
  • CYP3A4 inducers (e.g. phenobarbital, rifampicin, St John's wort, bosentan, efavirenz, modafinil) lower levels; not recommended

Pregnancy and breastfeeding

  • Pregnancy: limited data; as a precaution, use should preferably be avoided
  • Breast-feeding: minimal concentrations in breast milk; weigh benefits and risks

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • VyduraPfizer Europe MA EEIG · EMEA/H/C/005725

Source: European Medicines Agency (EMA), product information

Turkey

  • Nurtec PfizerPFİZER PFE İLAÇLARI A.Ş. · 3 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Vydura
Liechtenstein
Vydura
Norway
Vydura

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Vydura – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/vydura-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC N02CD.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.